Initial Results From Phase 1/2 Study of the RET-Selective Inhibitor Vepafestinib in Patients With RET-Aberrant Solid Tumors

Authors

• K. Yoh
• Y. Shinno
• V. Velcheti
• V. Subbiah
• N. Lakhani
• K. Ohashi
• Shirish M. Gadgeel, Henry Ford HealthFollow
• S. Kitano
• M. Johnson
• H. Wakelee
• A. Ono
• K. Nishino
• E. Miyauchi
• T. Kurata
• A. Drilon

Recommended Citation

Yoh K, Shinno Y, Velcheti V, Subbiah V, Lakhani N, Ohashi K, Gadgeel SM, Kitano S, Johnson M, Wakelee H, Ono A, Nishino K, Miyauchi E, Kurata T, Drilon A. Initial Results From Phase 1/2 Study of the RET-Selective Inhibitor Vepafestinib in Patients With RET-Aberrant Solid Tumors. J Thorac Oncol 2025; 20(10):1.

Document Type

Conference Proceeding

Publication Date

10-1-2025

Publication Title

J Thorac Oncol

Keywords

Vepafestinib, RET-selective inhibitor, RET-aberrant solid tumors, Oncology, Respiratory System

Volume

20

Issue

10

First Page

1